These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 9738562)

  • 1. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
    Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
    Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    Tsavaris N; Kosmas C; Vadiaka M; Koufos C
    BMC Cancer; 2002; 2():2. PubMed ID: 11860608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mature results from three large controlled studies with raltitrexed ('Tomudex').
    Cunningham D
    Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
    Popov I; Carrato A; Sobrero A; Vincent M; Kerr D; Labianca R; Raffaele Bianco A; El-Serafi M; Bedenne L; Paillot B; Mini E; Sanches E; Welch J; Collette L; Praet M; Wils J
    Eur J Cancer; 2008 Oct; 44(15):2204-11. PubMed ID: 18707870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
    Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
    Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
    Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
    Zalcberg JR; Cunningham D; Van Cutsem E; Francois E; Schornagel J; Adenis A; Green M; Iveson A; Azab M; Seymour I
    J Clin Oncol; 1996 Mar; 14(3):716-21. PubMed ID: 8622016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
    J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
    Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
    Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
    Kerr DJ
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
    J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS; Faulds D
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
    Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
    Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
    Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G
    Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.
    Zalcberg J; Kerr D; Seymour L; Palmer M
    Eur J Cancer; 1998 Nov; 34(12):1871-5. PubMed ID: 10023308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.